目的:分析我国免疫检查点抑制剂(immune checkpoint inhibitors，ICIs)致甲状腺相关不良反应(thyroid-immune related adverse events，T-irAEs)的特点及规律，为临床合理用药提供参考。方法:检索中国知网、万方、维普数据自建库至2022年12月关于T-irAEs的文献报道，提取个案数据并进行分析。结果:最终纳入25篇文献，共28例个案报道，患者平均年龄(61。59±10。60)岁，原发疾病为肺癌者最多(64。29％)，T-irAEs发生时间多为用药后3。03个周期，约66。54d，其中报道的不良反应类型有亚临床甲状腺功能减退3例(10。71％)、甲状腺功能减退13例(46。43％)、甲状腺功能亢进7例(25。00％)及甲状腺炎5例(17。86％)。结论:文献分析显示我国T-irAEs以甲状腺功能减退为多，在ICIs治疗过程中，应加强监测，及时识别，保障患者用药安全。
Literature review of thyroid related adverse events by immune checkpoint inhibitors in China
OBJECTIVE To explore the characteristics and regular patterns of thyroid-immune related adverse events(T-irAEs)after using immune checkpoint inhibitors(ICIs)in China and provide references for clinical rational drug dosing.METHODS Literatures about T-irAEs were retrieved from the databases of China National Knowledge Infrastructure(CNKI),Wanfang and VIP from the inceptions to December 2022.RESULTS A total of 28 cases in 25 literatures were included.Average age was(61.59±10.60)years and primary disease was lung cancer(64.29％).The occurrence time of T-irAEs was 3.03 cycles and approximately 66.54 days after medication.The relevant T-irAEs included subclinical hypothyroidism(n=3,10.71％),hypothyroidism(n=13,46.43％),hyperthyroidism(n=7,25.00％)and thyroiditis(n=5,17.86％).CONCLUSION A large majority of T-irAEs is hypothyroidism in China.During ICIs dosing,monitoring should be strengthened to identify T-irAEs in time to ensure the safety of drug dosing.
immunecheckpoint inhibitorsadverse reactionthyroid dysfunctionrational drug use
NETL
NSTL
万方数据
